Arbutus Biopharma Corp (ABUS) vs Beta Bionics, Inc. (BBNX)

A side-by-side comparison of Arbutus Biopharma Corp and Beta Bionics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Arbutus Biopharma Corp logo
ABUS
Arbutus Biopharma Corp
$926M
$4.69HealthcareDelayed quote: Oct 6, 2026, 9:30 AM EDT
Beta Bionics, Inc. logo
BBNX
Beta Bionics, Inc.
$851M
$18.91HealthcareDelayed quote: Oct 6, 2026, 9:30 AM EDT

Total return — ABUS vs BBNX

growth of $100 · dividends reinvested · last 2y
ABUS +39.4% (+18.1%/yr)BBNX -19.8% (-10.4%/yr)ABUS compounded faster over this window
50100150Start $1002026$139$80
ABUS BBNX

ABUS vs BBNX: by the numbers

  • •ABUS is the larger company ($926M vs $851M market cap).
  • •ABUS is profitable (84.23% net margin) while BBNX runs a net loss (-61.32%).

Metrics side by side

Valuation

MetricABUSBBNX
P/E ratio6.01N/A
Forward P/E6.34N/A
P/S ratio5.107.15
P/B ratio3.583.32
EV / EBITDA6.19N/A

Profitability

MetricABUSBBNX
Gross margin99.98%58.31%
Operating margin-192.08%-69.75%
Net margin84.23%-61.32%
ROE59.16%-28.46%
ROIC54.39%-31.17%

Growth (annualized)

MetricABUSBBNX
Revenue CAGR (5Y)85.17%N/A
Total return CAGR (5Y)2.19%N/A

Frequently asked

Is ABUS or BBNX more profitable?
ABUS runs the higher net margin — ABUS at 84.23% versus BBNX at -61.32%.

Go deeper

Full ABUS analysisFull BBNX analysisInteractive comparison tool

Dig into the metrics

Arbutus Biopharma P/E ratioArbutus Biopharma ROEBeta Bionics ROEArbutus Biopharma operating marginBeta Bionics operating marginArbutus Biopharma revenue growthBeta Bionics revenue growthArbutus Biopharma free cash flowBeta Bionics free cash flow

Arbutus Biopharma & Beta Bionics appear in these rankings

Fastest Revenue Growth StocksHighest ROE StocksHighest ROIC StocksLowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.